# DESCRIPTION

- claim priority and government support

## TECHNICAL FIELD

- introduce fungal infections and diseases

## BACKGROUND ART

- describe Candida albicans and its infections
- discuss existing antifungal agents and immunization strategies

## DISCLOSURE OF INVENTION

- describe new peptide vaccines and monoclonal antibodies against candidiasis

## MODES FOR CARRYING OUT THE INVENTION

- describe Fba peptide vaccine development
- design vaccines for additional fungal diseases
- modify Fba peptide sequence for improved effectiveness
- define vaccine-related terms and concepts
- outline pharmaceutical composition and administration methods

### Section A: Peptide Vaccines

- describe Candida strains and culture conditions
- detail mice and dendritic cell isolation
- outline immunization procedures with peptide pulsed dendritic cells
- summarize serological assays and monoclonal antibody production
- describe inhibition ELISA, SDS-PAGE, immunofluorescence, and flow cytometric analysis
- describe peptide vaccine experiments
- motivate protection against disseminated candidiasis
- summarize antibody responses to peptide vaccines
- evaluate protection against different C. albicans strains
- compare vaccine efficacy in BALB/c and C57BL/6 mice
- demonstrate passive protection with anti-Fba peptide immune sera
- introduce peptide vaccines
- motivate Fba peptide protection
- describe Fba peptide administered with alum
- characterize Fba monoclonal antibody
- demonstrate IgM MAb protection
- summarize Fba peptide vaccine results
- introduce development of more general fungal vaccines
- design new peptides for broader fungal species
- describe Fba2, Fba3, Fba4, and Met6-2 peptides
- conclude peptide vaccine development
- describe peptide vaccines efficacy
- detail immunization and serological assays
- evaluate protection against disseminated candidiasis
- design and test methylated Fba peptides
- analyze reactivity with anti-Fba immune sera
- test antibody response to modified peptides

### Section B: Conjugate Vaccines

- describe Candida albicans strains and mouse strains
- outline synthesis of conjugate vaccine
- detail immunizations of mice
- describe serological assays
- outline fungal challenge and assessment of protection
- describe passive transfer of immune sera
- summarize statistical analysis
- describe conjugate vaccine
- evaluate immunogenicity of β-(Man)3-Fba conjugate
- test adjuvants for β-(Man)3-Fba conjugate
- modify β-(Man)3-Fba conjugate with tetanus toxoid
- evaluate immunogenicity of β-(Man)3-Fba-TT conjugate
- test β-(Man)3-Fba-TT conjugate without adjuvant
- demonstrate passive protection with β-(Man)3-Fba-TT conjugate
- evaluate β-(Man)3-Fba-TT conjugate in outbred mice
- analyze antibody isotype responses
- describe synthesis of β-Man trisaccharide-Fba and Fba peptide conjugated to tetanus toxoid

## Reagents and General Methods

- list reagents and general methods

### Fmoc-Lys(ivDde)-NovasynTG

- synthesize Fmoc-Lys(ivDde)-NovasynTG

### H-YGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(ivDde)-NovasynTG

- assemble peptide using automated synthesizer

### AcYGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH (Compound 1)

- synthesize Compound 1

### HS(CH2)2CO-YGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH (Compound 2)

- synthesize Compound 2

### βMan3-S(CH2)2CO-YGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH (Compound 4)

- synthesize Compound 4

### Conjugation of the Peptides AcYGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH and βMan3-S(CH2)2CO-YGKDVKDLFDYAQE(SEQ ID NO: 1)-TEG-K(SATA)-OH to Tetanus Toxoid

- conjugate peptides to tetanus toxoid

